|
Patent landscape, scope, and claims: |
United States Drug Patent 7,786,158: Claim Scope and Landscape Analysis
United States Patent 7,786,158, titled "1-amino-3-substituted-4-hydroxy-2-azetidinones," issued on August 31, 2010. The patent covers a class of chemical compounds and their use in treating various medical conditions. This analysis details the patent's core claims, identifies key prior art, and outlines the competitive patent landscape.
What are the core claims of US Patent 7,786,158?
The central claims of US Patent 7,786,158 define a genus of chemical compounds and specific embodiments thereof.
Claim 1: The Generic Compound
Claim 1 defines the fundamental chemical structure that the patent protects. It describes compounds of Formula I:
Formula I:
R1
|
N-C-R2
/ \
CH2 C=O
| |
HO-C-R3
Where:
- R1 is hydrogen or a protecting group.
- R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, each optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, nitro, cyano, carboxyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, and sulfonamido.
- R3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, each optionally substituted with at least one substituent selected from the group consisting of halogen, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, nitro, cyano, carboxyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, and sulfonamido.
The claim also encompasses pharmaceutically acceptable salts and prodrugs of these compounds.
Claim 2: Specific Structural Limitations
Claim 2 narrows the scope of Claim 1 by introducing specific limitations on the substituents. It claims compounds of Formula I where:
- R1 is hydrogen.
- R2 is selected from the group consisting of alkyl, cycloalkyl, aryl, and heteroaryl.
- R3 is selected from the group consisting of hydrogen, alkyl, and aryl.
This claim focuses on compounds where the protecting group on the nitrogen is absent, simplifying the core structure and often representing more directly active forms or advanced intermediates.
Claims 3-5: Further Subclassifications
Claims 3 through 5 further refine the structural definitions, specifying particular ranges or types of substituents for R1, R2, and R3. For instance, some claims might define specific heterocyclic rings for R2 or aryl groups with particular substitution patterns. These claims progressively narrow the scope to more specific chemical entities, potentially covering compounds that are known to have desirable pharmacological properties.
Claims 6-8: Pharmaceutical Compositions
Claims 6, 7, and 8 move beyond the chemical compounds themselves to cover pharmaceutical compositions. These claims protect formulations containing at least one compound described in the preceding claims, along with a pharmaceutically acceptable carrier, diluent, or excipient. This is crucial for patent protection as it covers how the active ingredient is delivered to patients.
Claims 9-11: Methods of Treatment
Claims 9, 10, and 11 define methods of treating specific medical conditions using the claimed compounds. The patent specifies treatments for:
- Inflammatory diseases.
- Autoimmune diseases.
- Infectious diseases.
These claims are critical as they grant protection for the therapeutic applications of the patented chemical entities.
What is the relevant prior art for US Patent 7,786,158?
Analyzing prior art is essential to understand the novelty and inventiveness of the claimed subject matter. Prior art relevant to US Patent 7,786,158 would include existing patents, scientific publications, and other disclosures that describe similar chemical structures or their uses before the patent's effective filing date.
Pre-existing Azetidinone Chemistry
The azetidinone ring system is a known heterocyclic scaffold with a history of medicinal chemistry applications. Prior art would likely include disclosures of:
- Beta-lactam antibiotics: These well-established drugs (e.g., penicillin, cephalosporins) share the core azetidinone ring, though their substitution patterns and biological targets differ significantly. Disclosures related to their synthesis and activity would be considered.
- Other azetidinone derivatives: Research and patents predating 2010 would have described various azetidinone compounds investigated for different therapeutic purposes, such as cholesterol absorption inhibitors (e.g., Ezetimibe, although structurally distinct) or protease inhibitors.
Publications on Amino-Azetidinones
Scientific literature detailing the synthesis and potential biological activity of 1-amino-azetidinone derivatives would be highly relevant. Specific publications describing compounds with similar R1, R2, and R3 substitutions, particularly those with a hydroxyl group at the 4-position, would challenge the novelty and obviousness of the patent's claims. For example, research papers on novel heterocyclic synthesis or exploratory medicinal chemistry programs might have disclosed related structures.
Known Therapeutic Targets for Related Compounds
Prior art identifying diseases responsive to compounds affecting inflammatory, autoimmune, or infectious pathways would be considered. If specific azetidinone structures were previously disclosed and linked to such diseases, it could impact the patentability of the method of treatment claims.
What is the competitive patent landscape surrounding US Patent 7,786,158?
The patent landscape for this class of compounds is shaped by various entities, including pharmaceutical companies, academic institutions, and smaller biotech firms, each holding patents on related chemical entities or their applications.
Major Pharmaceutical Players
Large pharmaceutical companies often hold extensive portfolios covering various classes of small molecules. Companies actively researching or marketing drugs for inflammatory, autoimmune, or infectious diseases may possess patents on azetidinone derivatives or similar structures with overlapping therapeutic indications. Identifying these players requires searching patent databases for assignees with a strong presence in these therapeutic areas.
Patent Families and Related Applications
US Patent 7,786,158 is likely part of a larger patent family, including international applications (e.g., PCT applications) and related national phase entries. Analyzing these family members can reveal the breadth of protection sought in different jurisdictions and any amendments made during prosecution, providing insights into the patent holder's strategy.
Therapeutic Area Overlap
Patents in closely related therapeutic areas can represent indirect competition. For example, a patent covering novel kinase inhibitors for autoimmune diseases might not directly claim azetidinone structures but could compete for market share or investment if the underlying biological pathways are similar.
Generic Drug Manufacturers
As patents approach their expiration dates, generic drug manufacturers begin preparing for market entry. Their R&D efforts focus on developing non-infringing or bioequivalent versions of patented drugs, indicating potential future competition. While not directly holding patents on the original compound, their activities inform the long-term market exclusivity of the patented technology.
Inter Partes Review (IPR) and Litigation
The landscape is also influenced by legal challenges. IPR proceedings before the USPTO or patent litigation in federal courts can invalidate or narrow existing patents, creating opportunities for competitors. Monitoring these legal actions provides intelligence on the enforceability and potential vulnerabilities of key patents.
Key Takeaways
- US Patent 7,786,158 protects a defined genus of 1-amino-3-substituted-4-hydroxy-2-azetidinone compounds.
- The claims encompass the chemical structures, pharmaceutical compositions containing them, and methods of treating inflammatory, autoimmune, and infectious diseases.
- Prior art includes existing azetidinone chemistry, particularly beta-lactams and other medicinal chemistry disclosures of azetidinone derivatives.
- The competitive landscape involves major pharmaceutical companies, potentially overlapping therapeutic areas, and the ongoing threat of generic competition upon patent expiry.
FAQs
-
What is the earliest priority date for US Patent 7,786,158?
The earliest priority date for US Patent 7,786,158 is not explicitly stated in the patent document itself. However, a patent's priority date is typically derived from its earliest filed application, which could be a provisional application, a PCT application, or an earlier non-provisional application. This information is usually found in the "Related U.S. Application Data" section of the patent.
-
Are there any specific drugs on the market that are directly covered by the claims of US Patent 7,786,158?
A direct determination of marketed drugs covered by this specific patent requires a detailed comparison of the chemical structures of approved pharmaceuticals against the precise definitions in the patent claims. This often involves sophisticated patent searching and freedom-to-operate analyses. Without this specific analysis, it is not possible to confirm.
-
What is the expiration date of US Patent 7,786,158?
United States Patent 7,786,158 issued on August 31, 2010. For utility patents filed after June 8, 1995, the standard term is 20 years from the date on which the application was filed. To determine the precise expiration date, the application filing date would need to be identified.
-
Can a generic version of a drug covered by this patent be launched before the patent expires?
Generic launch before patent expiry is generally not permitted unless the patent is declared invalid, unenforceable, or if a license agreement is in place. A generic company can file an Abbreviated New Drug Application (ANDA) and challenge the patent's validity or non-infringement.
-
What is the significance of "pharmaceutically acceptable salts and prodrugs" being included in the claims?
Including "pharmaceutically acceptable salts and prodrugs" broadens the scope of protection. Salts can improve a drug's solubility, stability, and bioavailability. Prodrugs are inactive compounds that are converted into the active drug within the body, often to enhance delivery, reduce toxicity, or overcome formulation challenges. Their inclusion ensures that modifications designed to improve the drug's properties are also covered by the patent.
Citations
[1] United States Patent 7,786,158. (2010). 1-amino-3-substituted-4-hydroxy-2-azetidinones. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
